Debiopharm International Sa

This early-phase study is testing a new drug called Debio 0123 in 66 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. Participants receive the dr…

This study tests a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The drug blocks a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to find the right dose that safely lowers testosterone levels to slo…

This study tests a long-acting injection (Debio 4326) given once a year to children with central precocious puberty—a condition where puberty starts too early. The goal is to suppress hormone levels back to a pre-puberty range and pause physical changes. About 56 children aged 2 …